Description

Product Description

Antitumor agent-39 (CAS 159255-72-8) is a synthetic peptide compound with well-characterized antineoplastic properties. First disclosed in patent US20050009751A1 (compound 64), this compound represents a class of bioactive peptides with the ability to inhibit cancer cell growth, induce apoptosis, and modulate tumor microenvironmental responses. Its chemical nature, characterized by a stable peptide backbone and selective activity, makes it a promising tool in oncological drug research and development.

Peptide-based therapeutics such as Antitumor agent-39 have gained significant attention due to their high selectivity, low toxicity, and strong binding affinity toward target proteins involved in cancer progression. Antitumor agent-39 functions by interfering with key signaling pathways regulating cell survival and proliferation, leading to cancer cell cycle arrest and apoptosis.

In preclinical research settings, Antitumor agent-39 demonstrates broad-spectrum anticancer effects across multiple tumor types, including epithelial, hematologic, and solid tumors. Its mechanism of action likely involves mitochondrial apoptotic signaling, caspase activation, and inhibition of oncogenic kinases—hallmarks of therapeutic peptides under investigation for translational oncology.

This compound serves as an excellent molecular probe for understanding the mechanisms underlying peptide-based tumor suppression, as well as for developing improved analogs with enhanced pharmacokinetic and stability profiles.

Product Specifications

Mechanism of Action

Antitumor agent-39 exerts its anticancer effects by targeting multiple cellular signaling pathways responsible for cell proliferation, survival, and differentiation. As a peptide compound, it displays a multi-modal mechanism combining receptor-mediated and intracellular signaling disruption.

1. Induction of Apoptosis

One of the central mechanisms of Antitumor agent-39 involves activation of the intrinsic apoptotic pathway. The compound triggers mitochondrial membrane depolarization, promoting cytochrome c release and downstream caspase-3 and -9 activation. This leads to programmed cell death, reducing tumor cell viability and proliferation.

2. Inhibition of Cell Proliferation

Antitumor agent-39 impairs oncogenic kinase signaling (e.g., PI3K/AKT, MAPK, and ERK pathways), resulting in G1/S or G2/M cell cycle arrest. This cell cycle blockade prevents uncontrolled cancer cell division, effectively suppressing tumor growth in vitro.

3. Modulation of Tumor Microenvironment

The compound also exhibits anti-angiogenic and immunomodulatory activities, likely through the downregulation of vascular endothelial growth factor (VEGF) and suppression of inflammatory cytokines that sustain tumor progression.

4. Enhancement of Cellular Stress Response

Antitumor agent-39 induces oxidative stress and ER stress within tumor cells, which further accelerates apoptotic signaling. By disrupting intracellular homeostasis, it enhances the susceptibility of cancer cells to programmed death.

5. Potential Synergy with Other Anticancer Agents

When used in combination with chemotherapeutics or radiation, Antitumor agent-39 shows potential to enhance therapeutic efficacy while possibly reducing off-target toxicity. Its selective activity offers a mechanistic advantage in combination therapy research for resistant tumor types.

In summary, Antitumor agent-39 is a mechanistically diverse peptide that operates through apoptosis induction, signaling inhibition, and microenvironmental modulation to exert its potent antitumor activity.

Side Effects

While comprehensive toxicological data for Antitumor agent-39 are not available, general preclinical observations and related peptide analogs indicate possible side effects associated with potent cytotoxic and signaling-modulating peptides:

• Cellular cytotoxicity at high concentrations due to strong pro-apoptotic action.

• Transient mitochondrial stress, leading to reversible metabolic inhibition.

• Possible immunogenicity upon repeated exposure in animal models.

• Off-target effects involving non-tumor proliferative cells at supra-physiological doses.

• Minimal systemic toxicity observed in localized applications (based on peptide analog studies).

Proper experimental dosing and handling conditions are recommended to ensure selective cellular targeting and minimal nonspecific cytotoxicity during in vitro or in vivo testing.

Disclaimer

This product is for research use only (RUO). Not intended for human or veterinary use. Laboratory-grade compound supplied for controlled research applications.

Keywords

Antitumor agent-39, CAS 159255-72-8, peptide anticancer compound, tumor inhibitor peptide, apoptosis inducer, antineoplastic peptide, cancer cell apoptosis, caspase activator, mitochondrial apoptosis, US20050009751A1 compound 64, cancer therapeutic peptide research, oncology peptide analog.

Shipping Guarantee

All peptide compounds are shipped under validated temperature-controlled conditions with full traceability and insurance coverage to ensure product integrity and quality.

Transaction Guarantee

We guarantee secure international transactions, authenticity verification, and availability of batch-specific analytical data (HPLC, MS) for all peptide compounds.